Shenzhen Hepalink Pharmaceutical Group Co (SZSE:002399) Change In Receivables : ¥0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Shenzhen Hepalink Pharmaceutical Group Co Change In Receivables?

Shenzhen Hepalink Pharmaceutical Group Co's change in receivables for the quarter that ended in Mar. 2024 was ¥0 Mil. It means Shenzhen Hepalink Pharmaceutical Group Co's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Shenzhen Hepalink Pharmaceutical Group Co's change in receivables for the fiscal year that ended in Dec. 2023 was ¥271 Mil. It means Shenzhen Hepalink Pharmaceutical Group Co's Accounts Receivable declined by ¥271 Mil from Dec. 2022 to Dec. 2023 .

Shenzhen Hepalink Pharmaceutical Group Co's Accounts Receivable for the quarter that ended in Mar. 2024 was ¥1,152 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Shenzhen Hepalink Pharmaceutical Group Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 76.58.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Shenzhen Hepalink Pharmaceutical Group Co's liquidation value for the three months ended in Mar. 2024 was ¥-197 Mil.

Shenzhen Hepalink Pharmaceutical Group Co Change In Receivables Historical Data

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Hepalink Pharmaceutical Group Co Change In Receivables Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-479.16

-346.75

141.77

-176.10

270.55

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Shenzhen Hepalink Pharmaceutical Group Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

Shenzhen Hepalink Pharmaceutical Group Co (SZSE:002399) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Shenzhen Hepalink Pharmaceutical Group Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1152.424	/	1373.252	*	91
=	76.58

2. In Ben Graham's calculation of liquidation value, Shenzhen Hepalink Pharmaceutical Group Co's accounts receivable are only considered to be worth 75% of book value:

Shenzhen Hepalink Pharmaceutical Group Co's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2504.769	-	6736.458	+	0.75 * 1152.424	+	0.5 * 6341.628
=	-197

Shenzhen Hepalink Pharmaceutical Group Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Shenzhen Hepalink Pharmaceutical Group Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhen Hepalink Pharmaceutical Group Co (SZSE:002399) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Hepalink Pharmaceutical Group Co Ltd (SZSE:002399) » Definitions » Change In Receivables

Traded in Other Exchanges

09989:Hong Kong

Address

No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057

Website

https://www.hepalink.com

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business and Others. Geographical presence of company is in Hong Kong, United States of America, Europe, Mainland China and Other countries. Majority of the company's revenue comes from USA and Europe.

Executives

Zhang Ping	Director
Li Li	Director
Kong Yun	Executives
Li Tan	Directors, executives

Shenzhen Hepalink Pharmaceutical Group Co (SZSE:002399) Headlines

No Headlines